The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Researchers at New York University have devised a mathematical approach to predict the structures of crystals—a critical step in developing many medicines and electronic devices—in a matter of ...

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating on October 28. Tyler Van Buren has ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update. "Regeneron had a strong third quarter marked by 11% ...

There is no cure for COPD, but it can be managed and treated by working with your healthcare team to develop a plan to keep your COPD under control. Along with quitting smoking, staying up to date ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

and Dupixent for immunological and inflammatory diseases (such as atopic dermatitis, asthma, and COPD). While Eylea is nearing the end of its patent life and faces potential biosimilar competition ...